INTRODUCTION

58
Malignant bowel obstruction (MBO) is a common complication in patients with 59 advanced cancer with an incidence of 3%-15% (1) (2) (3) (4) (5) (6) . Symptoms include abdominal 60 pain, colic, nausea, vomiting, and abdominal swelling; these symptoms markedly impair 61 
Outcome Measures
112
The main outcome measure was the prescription patterns of drugs used concomitantly 113 with octreotide, i.e., the number of patients who received H2 blockers/PPIs and 114 corticosteroids. We also recorded the use of butylscopolamine. We defined the first 115 octreotide prescription day as the index day for each patient and identified any 116 concomitant drugs that were used on the index day. To extract information on concomitant 117 drugs, we limited the search to drugs using the Anatomical Therapeutic Chemical
118
Classification System (Supplemental Table 1 ), a drug classification system defined by the 119 World Health Organization. If such medications were administered on the index day, we 120 judged that there was concomitant use regardless of the period. For corticosteroids, 121 generic names and prescription period were also recorded. We calculated the daily 122 hydration volume of the index day and classified it as less than 1000 ml/day or 1000 123 mL/day or more.
124
As a secondary endpoint, for the subgroup of patients who had undergone 125 nasogastric tube (NGT) insertion on the index day, we calculated the total number of days 126 of NGT insertion. Although we believe that patient-reported outcomes such as intensity 127 of nausea or frequency of vomiting are important, such data was unavailable in the claims 128 database. Therefore, we decided to use claims data of NGT as a surrogacy outcome. The total number of days of NGT insertion was calculated from the first day when the patient 130 received octreotide (index day) to the day before the end of the NGT insertion or the day 131 the patient died or was discharged. Claims data recorded NGT insertion once daily as 132 long as it remained in place. In addition, information about disease-specific variables, performed to confirm the robustness of the results: 1) we divided the period of NGT insertion into 3 groups as follows: NGT removed within 4 days, within 7 days, and after 148 more than 14 days; 2) we performed subgroup analyses on patients with different 149 hydration volumes (<1000 mL/day vs. 1000 mL/day or more, 1000 mL/day or less vs.
150
more than 1000 mL/day, and <1500 mL/day vs. 1500 mL/day or more); and 3) we 151 performed subgroup analyses on patients with and without butylscopolamine use.
152
Because of the exploratory nature of this study, a p-value <0.05 was considered 153 statistically significant. Analyses were performed using SAS, version 9.4 (SAS Institute,
154
Cary, NC). 
188
Subgroup analyses on patients with a hydration volume of <1000 mL/day and 189 1000 mL/day or more revealed the essentially same results (Supplemental Table 2 ).
190
Sensitivity analyses using different cut-off points (i.e., ≤1000 mL vs. 1000 mL<, <1500 191 mL vs. ≤1500 mL) and subgroup analyses on the patients with or without the use of and psychiatric complications (14). However, the overall frequency of such side effects 216 was estimated to be low in previous studies (22, 24) . As there is still uncertainty regarding 217 both the benefits and potentially harmful effects of corticosteroids for MBO, the benefit 218 of corticosteroids for MBO should be further evaluated in comprehensive outcomes in 219 both clinical trials and real-world studies. We found that 48% of our patients were managed without NGT. Thus, the pharmacological management of those patients is 221 relatively important.
222
Of note, a combination of acid-reducing agents such as H2 blockers/PPIs and 223 octreotide resulted in prolonged NGT administration as compared with octreotide alone.
224
The potential interpretation is that patients with obstruction of the upper intestines were 225 more likely to receive acid-reducing agents and were less likely to experience the benefits 226 of octreotide (24). Further studies are necessary to confirm why the use of acid-reducing 227 agents is associated with poor outcomes in patients with MBO.
228
This study has several strengths. First, the study was designed based on real- it is unclear whether this benefit outweighed the adverse effects of corticosteroids; thus, 236 further studies addressing these issues are warranted. Third, the definition of concomitant 237 use was based on only the index day, and differences in the timing of administration and MBO severity was not investigated. Finally, this database contained no data about the 239 reasons for NGT insertion and removal. Although we believe it is reasonable to regard 240 NGT removal as an index of improvement because surgical patients were excluded, our 241 results should be interpreted with caution because of the nature of this study.
242
In summary, we found that octreotide alone was used in the majority of patients, 243 and use of corticosteroids was more likely to be associated with early NGT removal. 
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